Latest Breaking News On - China structural reform fund - Page 8 : comparemela.com
China s DMall hires three banks for over $500 million U S IPO: sources
reuters.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from reuters.com Daily Mail and Mail on Sunday newspapers.
China s DMall hires three banks for over $500 million U S IPO: sources
reuters.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from reuters.com Daily Mail and Mail on Sunday newspapers.
Chinese Biotherapeutics Firm Transcenta Bags $105 Million From Sequoia, LAV, and Others
Liya Su / Dec 24, 2020 04:45 PM / Business & Tech
Chinese global biotherapeutics company Transcenta Holding Limited, which had raised an undisclosed equity financing from China Capital Management in June this year, said on Wednesday that it has garnered $105 million in a crossover financing led by China Structural Reform Fund.
The latest round attracted a slew of new investors including Qatar Investment Authority, Chinese property developer Country Garden Venture Capital, and others.
Existing backers Sequoia Capital China, life science-focused Lilly Asia Ventures (LAV), China Merchants Capital’s sub-fund CCT China Merchants Fund, and Teng Yue Partners also joined the round, the investee said in a statement.
Transcenta Holding Limited, a global biotherapeutics company with integrated capabilities in discovery, development and manufacturing of antibody-based therapeutics, completed a 105m USD crossover financing.
China Structural Reform Fund led the financing round, participated by new investors including Country Garden Venture Capital, Qatar Investment Authority, and other prominent institutional investors. Existing investors including CCT China Merchants Fund, Lilly Asia Ventures, Teng Yue Partners, Sequoia Capital China and others also participated in this round.
The proceeds from new funding will be used to accelerate ongoing clinical programs and prepare for commercialization.
Led by Dr. Jonathan Y. Zhao, Co-Founder and Chairman, and Dr. Xueming Qian, Co-Founder and CEO, Transcenta is a global biotherapeutics company that fully integrates antibody-based biotherapeutics discovery, development and manufacturing. Transcenta has established global footprint with Discovery and
vimarsana © 2020. All Rights Reserved.